Эгоистичная митохондрия. Как сохранить здоровье и отодвинуть старость

Hipkiss A. R. Aging, proteotoxicity, mitochondria, glycation, NAD and carnosine: possible inter-relationships and resolution of the oxygen paradox. Front Aging Neurosci. 2010 Mar 18;2:10. doi:10.3389/fnagi.2010.00010. Hipkiss A. R. Mitochondrial dysfunction, proteotoxicity, and aging: causes or effects, and the possible impact of NAD+-controlled protein glycation. Adv Clin Chem. 2010;50:123–50.

Ho J. K., Duclos R. I. Jr, Hamilton J. A. Interactions of acyl carnitines with model membranes: a (13) C-NMR study. J Lipid Res. 2002 Sep; 43(9):1429–39. doi:10.1194/jlr.M200137-JLR200.

Kelley D. E., Mandarino L. J. Fuel selection in human skeletal muscle in insulin resistance: a reexamination. Diabetes. 2000 May; 49(5):677–83. doi:10.2337/diabetes.49.5.677.

Kelley D. E., Simoneau J. A. Impaired free fatty acid utilization by skeletal muscle in noninsulin-dependent diabetes mellitus. J Clin Invest. 1994 Dec; 94(6):2349–56. doi:10.1172/JCI117600.

Kil I. S., et al. Glycation-induced inactivation of NADP(+)-dependent isocitrate dehydrogenase: implications for diabetes and aging. Free Radic Biol Med. 2004 Dec 1; 37(11):1765–78.

Li J. M., Shah A. M. Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology. Am J Physiol Regul Integr Comp Physiol. 2004 Nov; 287(5):R1014–R1030. doi:10.1152/ajp-regu.00124.2004.

Lin J., et al. Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature. 2002 Aug 15; 418(6899):797–801. doi:10.1038/nature00904.

Lindroos M. M., et al. m.3243A>G mutation in mitochondrial DNA leads to decreased insulin sensitivity in skeletal muscle and to progressive {betacell dysfunction. Diabetes. 2009 Mar; 58(3):543–9. doi:10.2337/db08-0981. Linnane A. W., Kovalenko S., Gingold E. B. The universality of bioenergetic disease. Age-associated cellular bioenergetic degradation and amelioration therapy. Ann NY Acad Sci. 1998 Nov 20;854:202–13. doi:10.1111/j.1749–6632.1998.tb09903.x.

Maasen J. A. Mitochondria, body fat and type 2 diabetes: what is the connection? Minerva Med. 2008 Jun; 99(3):241–51.

Maassen J. A., et al. Mitochondrial diabetes: molecular mechanisms and clinical presentation. Diabetes. 2004 Feb; 53 Suppl 1:S103–S109, doi:0.2337/diabetes.53.2007.S103.

Maassen J. A., et al. Mitochondrial diabetes and its lessons for common type 2 diabetes. Biochem Soc Trans. 2006; 34:819–23.

Morino K., et al. Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents. J Clin Invest. 2005 Dec 1; 115(12):3587–93. doi:10.1172/JCI25151. Patti M. E., et al. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc Natl Acad Sci U S A. 2003 Jul 8; 100(14):8466–71. Epub 2003 Jun 27. doi:10.1073/pnas.1032913100.

Petersen K. F., et al. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science. 2003 May 16; 300(5622):1140–2. doi:10.1126/science.1082889.

Ritov V. B., et al. Deficiency of subsarcolemmal mitochondria in obesity and type 2 diabetes. Diabetes. 2005 Jan; 54(1):8–14. doi:10.2337/diabe-tes.54.1.8.

Rocha M., et al. Mitochondrial dysfunction and oxidative stress in insulin resistance. Curr Pharm Des. 2013; 19(32):5730–41. Epub Feb 20 2013.

Rocha M., et al. Perspectives and potential applications of mitochondria-targeted antioxidants in cardiometabolic diseases and type 2 diabetes. Med Res Rev. 2014 Jan; 34(1):160–89. Epub 2013 May 3. doi:10.1002/med.21285. Rovira-Llopis S., et al. Mitochondrial dynamics in type 2 diabetes: pathophysiological implications. Redox Biology. 2017 Apr; 11:637–45. doi:10.1016/j.redox.2017.01.013.

Ryu M. J. et al. Crif1 deficiency reduces adipose OXPHOS capacity and triggers inflammation and insulin resistance in mice. PLoS Genet. 2013 Mar; 9(3):e1003356. Epub 2013 Mar 14. doi:10.1371/journal.pgen.1003356. Schrauwen P., et al. Uncoupling protein 3 content is decreased in skeletal muscle of patients with type 2 diabetes. Diabetes. 2001 Dec 1; 50(12):2870– 3. doi:10.2337/diabetes.50.12.2870.

Schrauwen P., Hesselink M. K. Oxidative capacity, lipotoxicity, and mitochondrial damage in type 2 diabetes. Diabetes. 2004 Jun; 53(6):1412–7. doi:10.2337/diabetes.53.6.1412.

Short K. R., et al. Decline in skeletal muscle mitochondrial function with aging in humans. Proc Natl Acad Sci U S A. 2005 Apr 12; 102(15):5618–23. doi:10.1073/pnas.0501559102.